Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study

#415

Introduction: A phase II study was designed to assess the activity and safety of metronomic oral capecitabine, bevacizumab, and octreotide (Xelbevoct) in metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). We also assessed the predictive role for progression free survival (PFS) of hypertension, proteinuria and vascular endothelial growth factor (VEGF) polymorphisms and the predictive role of vitamin D on proteinuria and PFS.

Aim(s): The primary study aim was the response rate, secondary aims were toxicity, PFS and overall survival.

Materials and methods: Forty-five patients, with WMD-NEN from various primary sites, prospectively received Octreotide LAR, 20-30 mg monthly, metronomic capecitabine, 2000 mg/daily and intravenous bevacizumab, 5 mg/kg every two weeks, till nine months. Bevacizumab was prosecuted till progression if indicated.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Brizzi M, Fazio N, Ferrero A, Nobili E, Volante M,

Keywords: bevacizumab,